Glioblastoma multiforme (GBM) is the most aggressive
primary brain tumor with a median survival of 12 to 15 months after diagnosis. Acquired chemoresistance, high systemic toxicity, and low penetration of the blood brain barrier by many anticancer drugs contribute to the failure of
anti-GBM therapies. To circumvent some of these obstacles, we tested a novel
prodrug approach to evaluate
anti-GBM efficacy by utilizing
serum albumin-binding
doxorubicin (Doxo),
aldoxorubicin (
Aldoxo), which is less toxic, is released from
albumin in an acidic environment and accumulates in
tumor tissues. A human GBM cell line that expresses a
luciferase reporter (U87-luc) was stereotactically injected into the left striatum of the brain of immunodeficient mice. Following initial
tumor growth for 12 days, mice were injected once a week in the tail-vein with
Aldoxo [24 mg/kg or 18 mg/kg of
doxorubicin equivalents-3/4 maximum tolerated dose (MTD)], Doxo [6 mg/kg (3/4 MTD)], or vehicle.
Aldoxo-treated mice demonstrated significantly slower growth of the
tumor when compared to vehicle-treated or Doxo-treated mice. Five out of eight
Aldoxo-treated mice remained alive more than 60 days with a median survival of 62 days, while the median survival of vehicle- and Doxo-treated mice was only 26 days. Importantly,
Aldoxo-treated mice exhibited high levels of Doxo within the
tumor tissue, accompanied by low
tumor cell proliferation (Ki67) and abundant intratumoral programmed cell death (cleaved caspase-3). Effective accumulation of
Aldoxo in
brain tumor tissues but not normal brain, its anti-
tumor efficacy, and low toxicity, provide a strong rationale for evaluating this novel
drug conjugate as a treatment for patients afflicted with GBM.